Related Experiment Video
Updated: Aug 5, 2026

06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
NCCN Practice Guidelines for Prostate Cancer
R R Bahnson1, G E Hanks, R P Huben
1James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, USA.
Oncology (Williston Park, N.Y.)
|February 24, 2001
Abstract:
Systemic therapies for prostate cancer are likely to improve, and as they do, they will have enormous impact on the treatment of high-risk and locally advanced cancers. Further technical improvements in radiotherapy and alternative local modalities, such as cryoablation, are also likely, and will bring even more options for local control. It is certain these guidelines will continue to evolve.

